This review discusses the treatment of primary, nonmetastatic HER2-positive breast cancer in the adjuvant and neoadjuvant settings-settings in which tremendous progress has been made.
Ursa Brown-Glaberman, MD
Advertisement
Articles by Ursa Brown-Glaberman, MD
Advertisement
Latest Updated Articles
HER2-Targeted Therapy for Early-Stage Breast Cancer: A Comprehensive ReviewPublished: April 15th 2014 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma
2
How ADCs are Replacing Chemotherapy as Breast Cancer Treatment
3
Daratumumab Approval May Be “Game Changer” in High-Risk Smoldering Myeloma
4
What Were The Most Impactful GU Oncology Data From ESMO 2025?
5
